Free-residue Nutrients for the Bowel Preparation of Colon Capsule Endoscopy
NCT ID: NCT02887573
Last Updated: 2017-02-07
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE4
62 participants
INTERVENTIONAL
2014-01-31
2017-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Different Bowel Preparations in Magnetically Controlled Capsule Endoscopy
NCT06313242
Colon Capsule Endoscopy (CCE) Versus Computed Tomographic Colonography (CTC) in the Identification of Colonic Polyps in a Screening Population.
NCT02754661
Effect of Simethicone on Bowel Preparation for Colonoscopy
NCT02548403
Comparison Between 3-L and 4-L Polyethylene Glycol in Bowel Preparation
NCT03356015
Bowel Preparation Regimen for Colon Capsule Endoscopy Procedure
NCT05726097
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Methods: Participants who underwent a diagnostic colonoscopy examination that demonstrated a colorectal polyps that required endoscopic treatment will be recruited to patients in the study. The first 32 participants receive a traditional low fiber diet two days before the test.Then the patients will take 2L polyethylene glycol (PEG) at 21:00-23:00 before the test day and 2L PEG at 05:00-07:00 on the test day for bowel preparation. The subsequent 30 participants receive two-days free-residue nutrients without other diet before the test.Then the patients will take 2L PEG at 05:00-07:00 on the examination day for bowel preparation. Then they will take 5mg mosapride citrate at 8:00 and ingest the colon capsule at 8:30.0.75L and 0.50L PEG are administered as boosters.And the therapeutic endoscopy will be given on the following day.Before the therapeutic colonoscopy, the participants will take 2L PEG. The colon capsule results will be reviewed by two experienced endoscopists who are blinded to first endoscopy results.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SINGLE_GROUP
OTHER
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Free-residue nutrients+PEG
Diet: Free-residue nutrients Free-residue nutrient will be given when the patients are hungry before the two days of the capsule day.There are no other diet in this arm.
Drug: PEG 2L PEG are used at 05:00-07:00 the morning of the test. Drug: Mosapride citrate The patients will take 5mg mosapride citrate at 8:00. Drug:PEG 0.75L and 0.50L PEG are administered as boosters for patients. Procedure: Colon capsule endoscopy The colon capsule will be ingested at 08:30 the day of the test.The images will be reviewed by two experienced endoscopists.
Procedure: Colonoscopy On the following day of the test.All participants will undergo therapeutic colonoscopy.
Free-residue nutrients
This trial evaluated the efficiency of free-residue nutrients for the bowel prepartion of CCE.
Colon capsule endoscopy
In the study,all patients should undergo two colonoscopies.The first is for examinations and the second for therapy.
2L PEG
2L PEG are laxatives for experiment group.
PEG
These PEG are for boosters. All patients will take 0.75L and 0.5L PEG for two boosters.
Mosapride citrate
5mg mosapride citrate are used to promote gastric motivity.
Low fiber diet+PEG
Diet: Low fiber diet Before the two days of the capsule day,when the patients hungry,low fiber diet wiil be given.
Drug: PEG 4L PEG are used at 21:00-23:00 the night before the test and 05:00-07:00 the morning of the test.
Drug: Mosapride citrate The patients will take 5mg mosapride citrate at 8:00. Drug:PEG 0.75L and 0.50L PEG are administered as boosters for patients. Procedure: Colon capsule endoscopy The colon capsule will be ingested at 08:30 the day of the test.The images will be reviewed by two experienced endoscopists.
Procedure: Colonoscopy On the following day of the test,All participants will undergo therapeutic colonoscopy.
Low fiber diet
Low fiber diet often used in the bowel prepartion of CCE. In this study, it is the control group.
Colon capsule endoscopy
In the study,all patients should undergo two colonoscopies.The first is for examinations and the second for therapy.
4L PEG
4L PEG are laxatives in the control group.
PEG
These PEG are for boosters. All patients will take 0.75L and 0.5L PEG for two boosters.
Mosapride citrate
5mg mosapride citrate are used to promote gastric motivity.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Free-residue nutrients
This trial evaluated the efficiency of free-residue nutrients for the bowel prepartion of CCE.
Low fiber diet
Low fiber diet often used in the bowel prepartion of CCE. In this study, it is the control group.
Colon capsule endoscopy
In the study,all patients should undergo two colonoscopies.The first is for examinations and the second for therapy.
2L PEG
2L PEG are laxatives for experiment group.
4L PEG
4L PEG are laxatives in the control group.
PEG
These PEG are for boosters. All patients will take 0.75L and 0.5L PEG for two boosters.
Mosapride citrate
5mg mosapride citrate are used to promote gastric motivity.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* underwent a diagnostic OC that demonstrated colorectal polyps that required endoscopic treatment.
Exclusion Criteria
2. prior major abdominal surgery of the gastrointestinal tract, known or suspected bowel obstruction
3. cardiac pacemaker/implanted electromedical device
4. pregnant or nursing women
5. any allergy or contraindication to the drugs used in the study.
6. refused to sign a informed consent.
18 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Kaichun Wu
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Kaichun Wu
President of Xijing Hospital of Digestive Diseases
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Wu Kaichun, phD
Role: STUDY_DIRECTOR
Xijing Hospital of Digestive Diseases
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
XijingHDD
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.